10-K: Veracyte Reports Strong 2025 Growth, Expands Cancer Diagnostics

Sentiment:

Annual Report 26 February 2026 4:32 PM

Veracyte, Inc. reported a significant increase in total revenue and net income for the fiscal year ended December 31, 2025, driven by strong growth in its Decipher Prostate and Afirma tests and strategic expansion into minimal residual disease diagnostics.

Delay expectedThe PAMA data reporting period for CPT 81546 (Afirma GSC), CPT 81542 (Decipher Prostate), and CPT 0016U (Decipher Bladder) is expected between May 1 through July 31, 2026, which could result in updated reimbursement rates effective January 1, 2027, potentially delaying the realization of new rates.Certain state agencies, including the New York State Department of Health, have been experiencing delays in their response time which may cause delay in receipt of corresponding approvals or renewals for tests.The process of obtaining FDA clearance, authorization, or approval for diagnostics can be expensive and uncertain, generally taking several months to several years, potentially delaying product launches.The new IVDR in the EU has increased regulatory requirements, potentially leading to delays in placing products on the market.

Better than expectedNet income increased significantly by 175% to $66.4 million in 2025, compared to $24.1 million in 2024.Total revenue grew by 16% to $517.1 million, driven by strong performance in core testing segments.Testing volume increased by 19%, indicating strong market adoption for key products like Decipher Prostate (27% growth) and Afirma (11% growth).

Summary

Total revenue increased 16% to $517.1 million in 2025 from $445.8 million in 2024.
Net income increased 175% to $66.4 million in 2025 from $24.1 million in 2024.
Testing revenue grew 18% to $493.2 million, primarily from Decipher Prostate (27% volume growth) and Afirma (11% volume growth).
Total diagnostic test volume increased 18% to 179,528 tests.
Acquired C2i Genomics in early 2024, adding whole-genome minimal residual disease (MRD) capabilities.
Plans to launch TrueMRD (MIBC MRD test) and Prosigna as an LDT for the U.S. market in the first half of 2026.
Divested the contract manufacturing portion of its French subsidiary, Veracyte SAS, in August 2025, resulting in a $20.5 million impairment charge and a $6.7 million loss on deconsolidation.
Maintains a strong cash position with $412.9 million in cash, cash equivalents, and short-term investments as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, with significant revenue and net income growth driven by core products and strategic expansion into new areas like MRD. The company's robust cash position and clear future growth drivers are positive, though macroeconomic uncertainties and regulatory complexities present ongoing challenges.

Positives

Total revenue increased 16% to $517.1 million for the year ended December 31, 2025.
Net income increased 175% to $66.4 million for the year ended December 31, 2025.
Testing revenue increased 18% to $493.2 million, driven by strong volume growth.
Decipher Prostate test volume grew 27% to approximately 102,000 tests.
Afirma test volume grew 11% to approximately 67,700 tests.
Total diagnostic test volume increased 18% to 179,528 tests.
Acquisition of C2i Genomics in early 2024 added whole-genome minimal residual disease (MRD) capabilities, expanding the company's reach across the cancer care continuum.
Medicare coverage for the metastatic indication for Decipher Prostate was approved with a retroactive effective date of October 18, 2024.
Expanded Medicare coverage for Afirma GSC took effect on July 28, 2024.
Strong cash and cash equivalents and short-term investments of $412.9 million as of December 31, 2025.
Management concluded that internal control over financial reporting was effective as of December 31, 2025.
Certified as a Great Place to Work in both the United States and Israel in 2025.

Negatives

Biopharmaceutical and other revenue decreased by $3.5 million, or 27%, due to the restructuring proceedings affecting Veracyte SAS in August 2025.
Recorded a $20.5 million non-cash impairment charge primarily related to the right-of-use assets, property, plant, and equipment, and certain tax credits of Veracyte SAS.
Incurred a $6.7 million loss on the deconsolidation of Veracyte SAS.
Professional fees increased by $11.9 million, primarily due to fees related to the Veracyte SAS collective proceedings petition filing and other consulting spend.
Contingent consideration decreased by $17.5 million due to revaluation, indicating that some milestones for the C2i acquisition were not achieved or expectations were reduced.
Ongoing macroeconomic factors such as inflation, volatile interest rates, and geopolitical challenges (e.g., Middle East conflict) may adversely impact business and operating results.
Reliance on sole suppliers for critical reagents, equipment, and other materials poses a risk of supply interruptions and higher costs.
Payer cost-containment tactics, such as prior authorization and the use of laboratory benefit managers, may limit utilization and reimbursement for tests.

Risks

Financial results currently depend mainly on sales of Decipher Prostate and Afirma tests, and insufficient revenue from these or other diagnostic tests may hinder business growth.
Inability to grow sales or successfully launch/commercialize new tests (Prosigna LDT, TrueMRD, Percepta Nasal Swab) could negatively affect future revenue growth.
Incurred losses in the past and could incur net losses in the future; may not sustain profitability.
Dependence on a few payers for a significant portion of revenue; risk of decreased reimbursement or coverage changes.
Physicians or patients may decide not to order/use tests due to increased costs, fees, or changing insurer policies.
Failure to comply with federal, state, and foreign licensing requirements could lead to loss of testing ability or business disruptions.
Acquisitions (like C2i) or other strategic transactions could disrupt business, cause dilution, or reduce financial resources; integration challenges may arise.
Future success and international growth depend on the ability to adapt, manufacture, and distribute tests as IVD tests.
Reliance on sole suppliers for reagents, equipment, and kit components; risk of supply interruptions or higher costs.
Inability to manage future growth effectively could make it difficult to execute business strategy.
Inability to support demand for tests, products, or services could harm business.
Changes in healthcare policy (e.g., ACA, PAMA, No Surprises Act, Chevron doctrine reversal) may adversely affect financial condition and operations.
FDA or foreign authorities regulating currently unregulated tests could incur substantial costs and delays.
Obtaining marketing authorization or certification for diagnostic tests is time-consuming, costly, and may not succeed.
Inability to compete successfully against other genomic testing companies (Myriad Genetics, MDxHealth, Exact Sciences, Natera, Guardant Health, etc.) or traditional methods.
Dependence on senior management team; loss of executives or inability to attract/retain skilled employees.
Complex billing process for diagnostic tests; substantial time and resources required for collection.
Internal sales force less successful than anticipated could diminish revenue.
Developing, commercializing, and gaining reimbursement for new products is lengthy and complex; failure to meet projected timelines.
International business exposes to regulatory, political, operational, financial, and economic risks, including potential disruptions to C2i Genomics operations in Israel due to the Middle East conflict.
Security breaches, data loss, or disruptions to data systems could compromise sensitive information and expose to liability.
Risks associated with data privacy issues, including evolving laws (GDPR, CCPA/CPRA, PIPL) and compliance efforts.
Inability to protect or successfully defend intellectual property effectively.
Involvement in intellectual property litigation, which may be time-intensive and costly.
Ability to use net operating loss carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code.
Inability to maintain effective internal control over financial reporting.
Stock price may be volatile.
Anti-takeover provisions in charter documents and Delaware law could discourage, delay, or prevent a change in control.
Quarterly operating results may fluctuate significantly or fall below guidance/expectations.
Adverse macroeconomic and market conditions (inflation, interest rates, geopolitical events) may affect operating results.
Business and operations are subject to disruptions caused by pandemics, political events, war, terrorism, natural disasters, and other catastrophic events.
Exposure to risks associated with transactions denominated in foreign currency.
Inability to raise additional capital on acceptable terms in the future.
Effective tax rate may fluctuate, and obligations in tax jurisdictions may exceed accrued amounts.
Impairment in the value of goodwill or other intangible assets could have a material adverse effect.
Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations.
Investor expectations of environmental, social, and governance (ESG) factors may impose additional costs and expose to new risks.

Future Outlook

Veracyte expects to continue expanding Decipher Prostate's market penetration and leadership position while sustaining strong growth for Afirma. The company is prioritizing the launch of TrueMRD, its minimal residual disease platform, and Prosigna as a laboratory-developed test for the U.S. market in the first half of 2026. Longer-term growth drivers include the global launch of IVD products and solving new cancer challenges with tests like the Percepta Nasal Swab. The company anticipates continued capital expenditures for infrastructure, commercial operations, and research and development, and believes that sufficient positive evidence may become available within the next 12 months to reverse a portion of the deferred tax asset valuation allowance.

Management Comments

"We believe that exceptional cancer care begins with exceptional diagnostics."
"Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions."
"Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets."
"We are focused on progressing patient care from the current standard to a more individualized approach, leveraging each patient's unique cancer biology to improve their outcomes."
"We have no current plans to issue any shares of preferred stock."
"We believe our primary competition in MRD for MIBC is Natera, Inc."
"We pride ourselves on our strong culture, which encourages innovation, collaboration, and mutual respect."
"We believe our strength across these areas form a barrier to entry and a competitive advantage."
"Our specialist channels and relationships allow us to enter the cancer care continuum at the beginning of a cancer patient's journey, which positions us to more easily move down through that journey from diagnosis through treatment and monitoring."
"We believe that PAMA and its implementing regulations are generally favorable to us."

Industry Context

StockSavvy.ai notes that Veracyte's strong growth in core diagnostic tests (Decipher Prostate, Afirma) and strategic expansion into minimal residual disease (MRD) with C2i Genomics positions it well within the rapidly evolving oncology diagnostics market. The focus on both laboratory-developed tests (LDTs) in the U.S. and in vitro diagnostic (IVD) tests globally aligns with industry trends towards broader patient access and decentralized testing. The competitive landscape, particularly in MRD, is intense with established players like Natera, Inc., Guardant Health, Inc., and Exact Sciences Corporation, highlighting the importance of Veracyte's "whole-genome, AI-powered approach" for differentiation. The company's emphasis on evidence generation and guideline inclusion is critical for sustained reimbursement and adoption in a market increasingly scrutinized by payers.

Comparison to Industry Standards

Decipher Prostate is the only gene expression test included in the 2026 NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer, with Simon Level IB evidence, distinguishing it from competitors like Myriad Genetics, Inc. and MDxHealth, SA.
Afirma GSC's real-world meta-analysis showed 97% sensitivity, 88% specificity, and 99% negative predictive value (NPV), reinforcing its performance against competitors like Interpace Diagnostics Group, Inc. and ThyroSeq (marketed by Sonic Healthcare Limited).
Prosigna Breast Cancer Assay is recommended in guidelines from the National Comprehensive Cancer Network and the American Society of Clinical Oncology in the United States, and internationally by the National Institute for Health and Care Excellence (UK) and the European Society for Medical Oncology, competing with products from Exact Sciences Corporation, Myriad Genetics, Inc., and Agendia, Inc.
In bladder cancer, Veracyte is not currently aware of a direct genomic testing competitor offering prognostic purposes that matches the intended use population for its Decipher Bladder test, though DNA mutational analysis and traditional clinical methods are in use.
In minimal residual disease (MRD) for muscle-invasive bladder cancer (MIBC), Veracyte believes its primary competition is Natera, Inc., with other potential competitors including Guardant Health, Inc., Exact Sciences Corporation, Personalis, Myriad Genetics, Neogenomics, Inc., Quest Diagnostics, Billion-To-One, Caris Life Sciences or TempusAI, Inc.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Declassification	The board of directors, previously divided into three classes (2024, 2025, and 2026 Class) with staggered three-year terms, will terminate this division at the 2026 annual meeting of stockholders. Commencing with the 2026 annual meeting, all directors will be elected for a term of one year, expiring at the next succeeding annual meeting of stockholders.	2026 Annual Meeting of Stockholders	This change moves towards a more frequent election cycle for directors, potentially increasing board accountability to shareholders.
Stockholder Action Limitations	Stockholders may not take action by written consent, but may only take action at annual or special meetings of stockholders. Special meetings of stockholders may be called only by a majority of the board of directors, the chairman of the board, or the chief executive officer.	N/A (existing provision)	These provisions can deter hostile takeovers or delay changes in control by limiting the ability of stockholders to act outside of formal meetings or to easily call special meetings.
Director Removal and Vacancies	Directors serving in a class for a term expiring at the third annual meeting of stockholders following their election may be removed only for cause. Vacancies on the board of directors may, except as otherwise required by law, be filled only by a majority of directors then in office, even if less than a quorum.	N/A (existing provision)	These provisions enhance board stability and can make it more difficult for dissident shareholders to effect rapid changes to the board composition.
Voting Rights	No stockholder is permitted to cumulate votes at any election of directors.	N/A (existing provision)	Non-cumulative voting makes it harder for minority shareholders to elect directors, favoring majority control.
Amendment Requirements	Requires the vote of the holders of at least sixty-six and two-thirds percent of the voting power of all of the then outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class, to amend certain anti-takeover provisions.	N/A (existing provision)	This super-majority voting requirement makes it more difficult to alter key corporate governance provisions, reinforcing existing anti-takeover defenses.
Choice of Forum	The Court of Chancery of the State of Delaware is the sole and exclusive forum for certain internal corporate disputes, and federal district courts of the United States are the exclusive forum for Securities Act of 1933 claims.	N/A (existing provision)	This provision aims to centralize litigation in specific forums, potentially reducing legal costs and increasing predictability, but may limit stockholders' ability to choose a forum they find more favorable.
Cybersecurity Oversight	The board of directors, in coordination with the Audit Committee, oversees management of risks arising from cybersecurity threats, receiving regular presentations and reports on cybersecurity risks and incidents.	N/A (ongoing practice)	Demonstrates a structured approach to managing cybersecurity risks, enhancing corporate resilience and protecting sensitive data.

Legal Proceedings

On May 1, 2025, the company filed a complaint in federal court in the Eastern District of Texas alleging that Sonic Healthcare USA, Inc. is infringing three of the company's patents related to molecular testing of thyroid nodules.
On June 4, 2025, the company filed an amended complaint asserting two additional patents against Sonic Healthcare USA, Inc.
On July 21, 2025, Sonic Healthcare USA, Inc. filed an answer and a motion to dismiss.
On January 20, 2026, the court denied Sonic Healthcare USA, Inc.'s motion to dismiss.
The jury trial for this patent infringement case is currently scheduled for January 25, 2027.
The company is not currently a party to any other material legal proceedings.

Stakeholder Impact

Shareholders: Positive impact from increased revenue and net income, potential for stock appreciation, but dilution risk from future equity offerings for acquisitions. Volatility in stock price is a risk. Anti-takeover provisions may limit shareholder influence on control changes.
Employees: Positive impact from 'Great Place to Work' certification, equity awards as incentives (though volatility may affect value), and continued investment in R&D. Risk of loss of key personnel due to competitive industry.
Customers (Physicians/Laboratories): Benefit from high-performing diagnostic tests, expanded test menu (MRD, Prosigna LDT), and global IVD availability. Risk of delays in new test launches or regulatory approvals.
Patients: Improved outcomes through more confident diagnostic, prognostic, and predictive treatment decisions, avoiding unnecessary procedures. Risk of increased costs (co-payments) or limited access due to payer policies.
Suppliers: Continued business, but reliance on sole suppliers creates risk for both parties if supply is disrupted.
Creditors: Strong cash position and profitability reduce credit risk.

Next Steps

Launch TrueMRD (MIBC MRD test) in the first half of 2026.
Launch Prosigna as an LDT for the U.S. market in the first half of 2026.
Submit a tech assessment to MolDx for TrueMRD.
Develop Decipher Prostate as a quantitative polymerase chain reaction-based (qPCR-based) IVD test for international markets.
Continue to expand Decipher Prostate's penetration and leadership position.
Sustain strong growth for Afirma.
Invest in innovation to drive durable growth over the medium and long term.
Continue to develop and publish evidence for tests to inform clinical decisions and secure positive coverage decisions.
Monitor macroeconomic conditions and take financial or operational actions as appropriate.
Comply with new Quality Management System Regulation (QMSR) by February 2, 2026.
Jury trial scheduled for January 25, 2027, for patent infringement case against Sonic Healthcare USA, Inc.

Key Dates

Date	Description
December 31, 2022	Balance of stockholders' equity.
June 8, 2023	Company's stockholders approved the 2023 Equity Incentive Plan.
July 2023	European Commission adopted a new adequacy decision with respect to the United States under the EU-US Data Privacy Framework.
August 22, 2023	Promotion Letter for John Leite.
September 1, 2023	Effective date of Change of Control and Severance Agreement for John Leite.
September 11, 2023	Offer Letter for Phil Febbo.
October 2, 2023	Effective date of Change of Control and Severance Agreement for Phil Febbo.
December 31, 2023	Fiscal year end; Balance of stockholders' equity.
Early 2024	Acquisition of C2i Genomics, Inc. completed.
February 5, 2024	Closing Date of the C2i Acquisition.
May 2024	FDA published a final rule to phase out its policy of enforcement discretion over LDTs (later vacated).
July 28, 2024	New Local Coverage Determination (LCD) for Afirma GSC took effect through the MolDX program, providing expanded Medicare coverage.
September 2024	New LCD for Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers was finalized through the MolDX program.
October 18, 2024	Retroactive effective date for Medicare coverage of the metastatic indication for Decipher Prostate.
December 2024	Received confirmation that Technical Assessment for Decipher Prostate metastatic indication was approved by MolDx.
December 31, 2024	Fiscal year end; Balance of stockholders' equity.
March 31, 2025	Federal district court vacated the FDA's 2024 final rule to phase out its policy of enforcement discretion over LDTs.
May 1, 2025	Company filed a patent infringement complaint against Sonic Healthcare USA, Inc.
June 4, 2025	Company filed an amended patent infringement complaint against Sonic Healthcare USA, Inc.
June 30, 2025	Aggregate market value of common stock held by non-affiliates was approximately $1.7 billion.
July 4, 2025	The One Big Beautiful Bill Act (OBBBA) was signed into law, including tax reform provisions.
July 16, 2025	Marseille Commercial Court published a decision approving the divestiture of the contract manufacturing portion of Veracyte SAS to Helio Diagnostics SAS.
July 21, 2025	Sonic Healthcare USA, Inc. filed an answer and a motion to dismiss in the patent infringement case.
August 1, 2025	Effective date of the divestiture of Veracyte SAS contract manufacturing portion; Company ceased to have a controlling interest in Veracyte SAS.
August 2025	Israel's PPL, 5774-2024, took effect.
November 24, 2025	Marc Stapley (CEO) adopted a new Rule 10b5-1 trading plan.
December 5, 2025	Robert Epstein (director) adopted a new Rule 10b5-1 trading plan.
December 31, 2025	Fiscal year end; Balance of stockholders' equity.
January 1, 2026	Remaining C2i contingent consideration milestones had not been achieved and the contingent obligation expired.
January 20, 2026	Court denied Sonic Healthcare USA, Inc.'s motion to dismiss in the patent infringement case.
February 20, 2026	Number of shares of common stock outstanding was 79,458,427.
February 26, 2026	Date of the Annual Report on Form 10-K filing.
March 3, 2026	First trade under Marc Stapley's new trading plan scheduled.
March 6, 2026	First trade under Robert Epstein's new trading plan scheduled.
May 1 July 31, 2026	Expected PAMA data reporting period for CPT 81546 (Afirma GSC), CPT 81542 (Decipher Prostate), and CPT 0016U (Decipher Bladder).
August 31, 2026	Marc Stapley's trading plan effective until this date.
February 2, 2026	Device manufacturers must comply with the new Quality Management System Regulation (QMSR) by this date.
March 5, 2027	Robert Epstein's trading plan effective until this date.
January 25, 2027	Jury trial scheduled for the patent infringement case against Sonic Healthcare USA, Inc.
January 1, 2027	Potential effective date for updated reimbursement rates based on PAMA data, through December 31, 2029.
June 30, 2030	CE marks (IVDD self-certified or IVDR issued by EU notified regulatory bodies) will remain valid in Great Britain until this date.
July 2030	Expected effective date for the new regulatory regime for IVD medical devices in Great Britain.
December 31, 2031	European Commission adequacy decision for the United Kingdom's data protection framework is currently set to expire.
March 2040	The longest lease terms for the company's facilities extend to this date.

Recommendation

strong buy

Veracyte's 2025 results demonstrate robust financial health with significant revenue and net income growth, driven by strong adoption of its core Decipher Prostate and Afirma tests. The strategic expansion into the high-growth minimal residual disease (MRD) market through the C2i acquisition, coupled with planned launches of TrueMRD and Prosigna LDT in 2026, indicates a clear path for future growth and market diversification. While the divestiture of Veracyte SAS and ongoing macroeconomic and regulatory risks are noted, the company's strong cash position, effective internal controls, and leading position in key oncology diagnostic segments suggest a compelling investment opportunity for long-term growth. The declassification of the board of directors starting in 2026 also signals a move towards more responsive corporate governance.

Keywords

Cancer diagnostics, Molecular diagnostics, Genomic testing, Veracyte, VCYT, Decipher Prostate, Afirma, Prosigna, TrueMRD, Minimal residual disease, LDT, IVD, CLIA, C2i Genomics, Oncology, Corporate governance, Financial results, SEC 10-K, Healthcare technology, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.